Evidence map›Paper›PMID 41776242›Full record

ReviewNature reviews. Clinical oncology2026

Perioperative approaches for patients with biliary tract cancer.

Anudari Zorigtbaatar, Zhihao Li, Christian T J Magyar, Laia Aceituno, Anna Saborowski, Arndt Vogel, Robert C Grant, Grainne M O'Kane, Gonzalo Sapisochin

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Anudari ZorigtbaatarUniversity Health Network, HPB Surgical Oncology, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0002-5050-8967
Zhihao LiUniversity Health Network, HPB Surgical Oncology, Toronto, Ontario, Canada.
Christian T J MagyarUniversity Health Network, HPB Surgical Oncology, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0002-4570-949X
Laia AceitunoUniversity Health Network, HPB Surgical Oncology, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0001-5414-2408
Anna SaborowskiDepartment of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.ORCID http://orcid.org/0000-0003-4857-4276
Arndt VogelUniversity Health Network, Transplant Hepatology, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0003-0560-5538
Robert C GrantPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
Grainne M O'Kane *Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada. grainne.okane@ucd.ie.ORCID http://orcid.org/0000-0002-8690-403X
Gonzalo Sapisochin *University Health Network, HPB Surgical Oncology, Toronto, Ontario, Canada. gonzalo.sapisochin@vallhebron.cat.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biliary tract cancers, encompassing intrahepatic, perihilar and distal cholangiocarcinoma and gallbladder cancer, are a heterogeneous group of highly aggressive malignancies. Most patients have unresectable disease at first presentation, and even those who undergo surgery are likely to have disease recurrence. Newer approaches have included liver transplantation for selected patients, and the integration of locoregional and systemic therapies has expanded the number of patients who can benefit from surgery. The advent of immune-checkpoint inhibitors and targeted therapies for patients with advanced-stage disease has prompted the exploration of these agents in earlier-stage disease settings. Despite this progress, treatment algorithms remain complex, necessitating a multidisciplinary and individualized approach to patient management. Future research should focus on optimizing patient selection through biomarker-driven strategies, including the integration of molecular profiles to guide the selection of systemic therapy, as well as refining the criteria for surgery and transplantation. These improvements will require global collaboration and novel clinical trial designs. In this Review, we describe evolving perioperative strategies for the management of patients with biliary tract cancers and highlight emerging directions in the field.

Indexed as

Biliary Tract NeoplasmsNeoplasm Recurrence, LocalPerioperative CareAntineoplastic Combined Chemotherapy ProtocolsCapecitabineChemotherapy, AdjuvantCholecystectomyHepatectomyHumansImmune Checkpoint InhibitorsLiver TransplantationLymph Node ExcisionNeoadjuvant TherapyNeoplasm StagingPancreaticoduodenectomyPatient SelectionCapecitabineImmune Checkpoint Inhibitors

Identifiers

PMID41776242

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.